Argus Downgrades Perrigo Co. (PRGO) to Hold

Mylan (MYL) Ratings Placed on CreditWatch Negative by S&P Following Bid to Acquire Perrigo (PRGO)

Standard & Poor's Ratings Services today placed its ratings on Mylan Inc. (Nasdaq: MYL), including its 'BBB-' corporate credit rating, on CreditWatch with negative implications, following its announcement that it was in discussions to acquire Perrigo (NYSE:... More

Perrigo (PRGO) Placed on Watch Negative at Standard & Poor's on Potential Mylan Deal

Standard & Poor's Ratings Services today placed all of its ratings on Dublin-based Perrigo Co. plc, (NYSE: PRGO) including its 'BBB' corporate credit rating, on CreditWatch with negative implications. We estimate debt outstanding at Perrigo at about $5.8 billion.

We also separately placed all of our ratings on Mylan Inc., including our 'BBB-' corporate credit rating, on CreditWatch with negative implications.... More

No Immediate Impact Seen on Mylan (MYL), Perrigo (PRGO) Ratings Following Deal Announcement - Moody's

Moody's Investors Service commented on Mylan's (Nasdaq: MYL) proposal to acquire Perrigo (NYSE: PRGO) for $205 per share in cash and Mylan stock, for a total transaction value of nearly $30 billion. At this time, the announcement has no impact on the Baa3 ratings or stable outlook of either Mylan or Perrigo.

Mylan (MYL) Hits Session Highs, Rumors Abound

Mylan (NASDAQ: MYL) hit session highs early on Thursday on new rumors Pfizer (NYSE: PFE) could be interested in the company. There was also ongoing chatter Teva Pharma (NYSE: TEVA) could still be interested, despite Mylan's proposal to acquire Perrigo (NYSE: PRGO).

Chatter Suggests Teva (TEVA) Not Permitted to Make Hostile Bid for Mylan (MYL)

Chatter Suggests Teva (NYSE: TEVA) Not Permitted to Make Hostile Bid for Mylan (Nasdaq: MYL)

JP Morgan Comments on How Teva (TEVA) Might Respond to Mylan (MYL)/Perrigo (PRGO)

Analyst Chris Schott of JP Morgan commented on today's news Mylan (NASDAQ: MYL) made a $205 per share offer for Perrigo (NYSE: PRGO). In his view, the deal makes strategic and financial sense for Mylan. He also commented on how Teva Pharma (NYSE: TEVA) -- rumored to be interested in Mylan -- might respond. Overall, he thinks... More

Perrigo (PRGO) Confirms Mylan Offer, Will Review

Perrigo Company plc (NYSE: PRGO) notes the announcement made by Mylan NV (NASDAQ: MYL). Perrigo confirms that it has received an unsolicited, indicative proposal from Mylan regarding a possible offer for the Company.

The Board... More

Mylan (MYL), Perrigo (PRGO) Combo Makes Sense, Says Deutsche Bank

Analyst Gregg Gilbert of Deutsche Bank commented on news Mylan (NASDAQ: MYL) made a $205 offer to acquire Perrigo (NYSE: PRGO). In his view, the deal makes a "ton of sense."

"While we have not yet completed our pro forma analysis... More

Unusual 11 Mid-Day Movers 4/8: (AMCN) (CNYD) (CHNR) Higher; (FLML) (PSTR) (SYRX) Lower

AirMedia (Nasdaq: AMCN) 52.7% HIGHER; announced that Beijing Shengshi Lianhe Advertising Co., Ltd., a variable interest entity in China, which it currently controls through contractual arrangements (the "VIE structure"), has entered into a share transfer agreement to sell 5% equity interest of AirMedia Group Co., Ltd. ("AM Advertising") to Shenzhen Liantronics Co., Ltd, a company listed on the Shenzhen Stock Exchange for a consideration of RMB 150 million in cash (the "Transaction"), which reflected the total valuation of AM Advertising of RMB3 billion.

China Yida Holding, Co. (Nasdaq:... More

Teva Pharma (TEVA) on Watch on Mylan Headlines

Teva Pharma (NYSE: TEVA) is on watch on news Mylan N.V. (NASDAQ: MYL) made a proposal to acquire Perrigo Company plc (NYSE: PRGO) for $205/share.

Teva was seen as a suitor for Mylan.

Mylan (MYL) Proposes $205/Share Acquisition of Perrigo (PRGO)

Mylan N.V. (NASDAQ: MYL) announced that Mylan has made a proposal to acquire Perrigo Company plc (NYSE: PRGO) in a cash-and-stock transaction that would create a diversified, global pharmaceutical leader with an unmatched commercial and operating platform and a unique, one-of-a-kind profile. The combination of these highly complementary businesses would produce a company with critical mass in specialty brands, generics, over-the-counter (OTC) and nutritional products; a powerful commercial platform with reach across all customer channels; an exceptional high-quality operating platform; and opportunities to generate enhanced growth and deliver... More

Perrigo (PRGO) trading paused for volatility

Perrigo (NYSE: PRGO) trading paused for volatility.